安进Amgen Inc. (AMGN) 2012年年度报告「NASDAQ」.pdf

1、Dear Shareholders,2012 was an exceptional year for Amgen.We delivered for shareholders,positionedthe company for long-term growth,andcontinued to fulfill our mission to servepatients.Revenues rose 11 percent to$17.3 billion.Adjusted earnings per shareincreased 22 percent to$6.51.*Totalshareholder re

2、turn in 2012 was 36 percent,outperforming the S&P 500 and our peergroup.Our performance in 2012 reflectsstrength across our product portfolio,effectivecommercial execution,commitment tooperational efficiency,dedication of staff,andsound capital allocation decisions.Building onthis success,we entered

3、 2013 with momentumand confidence in our ability to execute ourlong-term strategy of reaching more patientsin more markets around the world.Delivering for ShareholdersMore than a year ago,we made a commitmentto return significant capital to shareholdersin the form of dividends and share buybacks,and

4、 we have delivered on that promise.Inearly 2013,we completed the$10-billionstock repurchase program announced inOctober 2011.Since January 2011,we haverepurchased more than 20 percent of ouroutstanding shares.In addition,since theinitiation of our first dividend in July 2011,we have raised the divid

5、end twice over theprevious quarterly amount by an average of30 percent.Continued Product MomentumAmgens product sales grew 9 percent in2012.Sales growth was led by Enbrel(etanercept),with solid contributions fromProlia(denosumab),XGEVA(denosumab),Sensipar(cinacalcet),Nplate(romiplostim),and Vectibix

6、(panitumumab).In 2012,two ofour products achieved more than$4 billion insales;three other products achieved morethan$1 billion in sales,as did our recentlylaunched denosumab franchise.We also sawour European business continue to grow in achallenging economic environment.Our products continue to show